The present results also go parallel with Izquierdo et al. [17] who found that after paricalcitol treatment of patients with renal disease, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. Here, IL6 is linked to kidney disorder.